文献速递膀胱癌与上尿路尿路上皮癌

局部晚期或转移性尿路上皮癌单克隆抗体治疗的生活质量:一项系统综述

Quality of Life with Monoclonal Antibody Therapies for Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review.
PubMed 文献 · Eur Urol Oncol · 2023-05-25

本系统综述检索2015年1月至2022年6月18日及2023年2月3日更新的数据库,纳入9项前瞻性研究共2364例接受单克隆抗体治疗的局部晚期或转移性尿路上皮癌患者。全球健康评分平均变化范围为-2.8至1.9,无研究显示全球健康评分显著改善,8项研究报道稳定,RANGE试验中全球健康评分下降。结论认为单克隆抗体治疗期间患者生活质量未恶化,证据确定性最高为中等,需进一步研究。

要点

  • 全球健康评分平均变化范围为-2.8至1.9,无研究显示显著改善。
  • 8项研究报道全球健康评分稳定,RANGE试验中评分下降。
  • 仅疼痛症状领域证据确定性为中等,其余HRQoL领域确定性低。

核心结论

  • 接受单克隆抗体治疗的la/mUC患者健康相关生活质量未随时间恶化。
  • HRQoL受治疗相关因素、肿瘤特征和患者健康状况等多因素影响。
  • 证据确定性最高为中等,需进一步研究。

研究设计与样本

  • 系统综述,检索MEDLINE及ASCO、ESMO会议数据库,时间范围为2015年1月至2022年6月18日,数据更新至2023年2月3日。
  • 纳入9项前瞻性试验(8项干预性试验和1项观察性研究),共2364例接受单克隆抗体治疗的la/mUC患者。
  • 排除局部疾病治疗、单纯放疗或化疗、荟萃分析、综述和病例报告。
  • 采用RoB2工具评估随机试验偏倚风险,采用GRADE方法评定结局证据强度,数据通过定性合成分析。

主要发现

  • 全球健康评分平均变化范围为-2.8至1.9。
  • 至少两项研究中便秘、疲劳和疼痛症状以及情感、躯体、角色和社会功能随治疗改善。
  • 无研究显示全球健康评分显著改善,8项研究报道稳定,RANGE试验中全球健康评分下降。
  • 仅2项研究根据RoB2评估具有高内部有效性。
  • HRQoL领域证据确定性低,仅疼痛症状领域为中等确定性。

关键数值与推荐

  • 全球健康评分平均变化范围为-2.8至1.9。
  • 仅疼痛症状领域证据确定性为中等,其余HRQoL领域确定性低。
  • 仅2项研究具有高内部有效性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仅2项研究根据RoB2评估具有高内部有效性。
  • HRQoL领域证据确定性低,仅疼痛症状领域为中等确定性。
  • 证据确定性最高为中等,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Monoclonal antibody (mAb) therapies have improved the prognosis for locally advanced or metastatic urothelial cancers (la/mUC) but little is known about health-related quality of life (HRQoL) with this mode of treatment. OBJECTIVE: To conduct a systematic review of changes in HRQoL global health and domain scores in patients with la/mUC receiving mAb therapies. EVIDENCE ACQUISITION: MEDLINE and the American Society of Clinical Oncology and European Society for Medical Oncology meeting databases were searched from January 2015 to June 18, 2022 in accordance with the Preferred Reported Items for Systematic Reviews and Meta-Analyses guidelines. Data were updated on February 3, 2023. Eligible studies were prospective trials assessing HRQoL in patients with la/mUC treated with mAbs. Patients treated for local disease or with radiotherapy or chemotherapy alone were excluded. Meta-analyses, reviews, and case reports were excluded. The validity of randomized trials was assessed using the Risk-of-Bias-2 (RoB2) tool and the strength of outcome evidence was rated using the Grading of Recommendations Assessment, Development and Evaluation approach. The data were analyzed via qualitative synthesis of the evidence. EVIDENCE SYNTHESIS: Of the 1066 studies identified, nine were included (2364 patients); eight were interventional trials and one was an observational study. The mean change in global health score ranged from -2.8 to 1.9. Constipation, fatigue and pain symptoms, and emotional, physical, role and social functioning improved with treatment in at least two studies. No study demonstrated a significant improvement in global health score. Eight studies reported stability. In the RANGE trial, the global health score decreased. Only two studies had high internal validity according to RoB2 assessment. The HRQoL domain certainty was low, with moderate certainty only for the pain symptom domain. Disease- and treatment-related symptoms, tumor shrinkage, and disease recurrence were correlated to HRQoL. CONCLUSIONS: Patient HRQoL with mAb therapies for la/mUC did not worsen over time. HRQoL is influenced by several factors related to treatment, tumor characteristics, and the patient's health condition. Evidence was moderate at best and further studies are needed. PATIENT SUMMARY: We reviewed the evidence on health-related quality-of-life for patients with advanced bladder cancer treated with antibody therapies. We found that quality of life does not worsen on treatment, and sometimes improves. We conclude that these treatments do not negatively affect quality of life, but further studies are needed to draw solid conclusions.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Annakib S, Fiteni F, Houédé N, et al. Quality of Life with Monoclonal Antibody Therapies for Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review. Eur Urol Oncol. 2023. PMID: 37244802. doi:10.1016/j.euo.2023.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。